Publicaciones en colaboración con investigadores/as de Mutua de Terrassa (211)

2024

  1. Feasibility and outcomes after dose reduction of immunochemotherapy in young adults with Burkitt lymphoma and leukemia: results of the BURKIMAB14 trial

    Haematologica, Vol. 109, Núm. 2, pp. 543-552

  2. Multi-ancestry genome-wide association meta-analysis of Parkinson’s disease

    Nature Genetics, Vol. 56, Núm. 1, pp. 27-36

  3. Sequential RAS mutations evaluation in cell-free DNA of patients with tissue RAS wild-type metastatic colorectal cancer: the PERSEIDA (Cohort 2) study

    Clinical and Translational Oncology

2023

  1. A second update on mapping the human genetic architecture of COVID-19

    Nature

  2. Association Between Insulin-Like Growth Factor-1 and Social Cognition in Huntington's Disease

    Movement Disorders Clinical Practice, Vol. 10, Núm. 2, pp. 279-284

  3. Author Correction: Elucidating causative gene variants in hereditary Parkinson’s disease in the Global Parkinson’s Genetics Program (GP2) (npj Parkinson's Disease, (2023), 9, 1, (100), 10.1038/s41531-023-00526-9)

    npj Parkinson's Disease

  4. Changes in Principal Caregiver Mood Affects the Mood of the Parkinson's Disease Patient: The Vicious Cycle of Illness

    Journal of Parkinson's disease, Vol. 13, Núm. 2, pp. 219-231

  5. Clinical utility of a personalized and long-term monitoring device for Parkinson's disease in a real clinical practice setting: An expert opinion survey on STAT-ON™

    Neurologia, Vol. 38, Núm. 5, pp. 326-333

  6. Cognitive impairment and dementia in young onset Parkinson’s disease

    Journal of Neurology, Vol. 270, Núm. 12, pp. 5793-5812

  7. Cohort Profile: PISCIS, a population-based cohort of people living with HIV in Catalonia and Balearic Islands

    International Journal of Epidemiology, Vol. 52, Núm. 4, pp. E241-E252

  8. Defining the causes of sporadic Parkinson’s disease in the global Parkinson’s genetics program (GP2)

    npj Parkinson's Disease, Vol. 9, Núm. 1

  9. Effectiveness and Safety of Teriflunomide in Relapsing–Remitting Multiple Sclerosis and Improvements in Quality of Life: Results from the Real-World TERICARE Study

    Neurology and Therapy, Vol. 12, Núm. 6, pp. 2177-2193

  10. Effectiveness and Safety of Ustekinumab in Elderly Patients with Crohn's Disease: Real World Evidence From the ENEIDA Registry

    Journal of Crohn's & colitis, Vol. 17, Núm. 1, pp. 83-91

  11. Evaluation of the validated intraoperative bleeding scale in liver surgery: study protocol for a multicenter prospective study

    Frontiers in Surgery, Vol. 10

  12. Falls Predict Acute Hospitalization in Parkinson's Disease

    Journal of Parkinson's disease, Vol. 13, Núm. 1, pp. 105-124

  13. Genomics improves risk stratifi cation of adults with T-cell acute lymphoblastic leukemia enrolled in measurable residual disease-oriented trials

    Haematologica, Vol. 108, Núm. 4, pp. 969-980

  14. Impact of Center-related Characteristics and Macroeconomic Factors on the Outcome of Adult Patients With Acute Lymphoblastic Leukemia Treated With Pediatric-inspired Protocols

    HemaSphere

  15. Key Factors Associated With Pulmonary Sequelae in the Follow-Up of Critically Ill COVID-19 Patients

    Archivos de Bronconeumologia, Vol. 59, Núm. 4, pp. 205-215

  16. Lenalidomide and dexamethasone maintenance with or without ixazomib, tailored by residual disease status in myeloma

    Blood, Vol. 142, Núm. 18, pp. 1518-1528

  17. Prevalence and Factors Associated with Drooling in Parkinson's Disease: Results from a Longitudinal Prospective Cohort and Comparison with a Control Group

    Parkinson's Disease, Vol. 2023